Although these results may be influenced by the small number of patients in each group, it may indicate that both PD-L1+ CSCs and CD4+ T cells could be indicative of rapid progression and poor prognosis in NSCLC patients. This evidence concerns the gene CD4 and non-small cell lung carcinoma.